Here, we have shown for the first time that blockade of hepatocyte-associated NF-κB activation by MnP (Figure 8) was able to ameliorate the obesity-mediated T2D phenotype, by diminishing the levels of TNF-α, MCP-1, and iNOS (Figure 7A,B), which are major inducers of NASH and insulin resistance [54,56]. Here, CCL2 is linked to metabolic dysfunction-associated steatohepatitis.